Income Statement Adaptimmune Therapeutics plc Börse Stuttgart
Stocks
473A
US00653A1079
Pharmaceuticals
|
Market Closed -
Börse Stuttgart
05:04:00 2026-05-21 EDT
|
5-day change | 1st Jan Change | ||
| 0.0100 EUR | -.--% |
|
-41.18% | -9.09% |
| 05-18 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 11-17 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
| Fiscal Period: December | 2016 (USD) | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 6.15M | 27.15M | 60.28M | 178M | 5.92M | |||||
Total Revenues | 6.15M | 27.15M | 60.28M | 178M | 5.92M | |||||
Cost of Goods Sold, Total | 111M | 128M | 127M | 149M | - | |||||
Gross Profit | -105M | -101M | -66.23M | 28.9M | 5.92M | |||||
Selling General & Admin Expenses, Total | 57.3M | 61.09M | 71.81M | 81.31M | 35.62M | |||||
R&D Expenses | - | - | - | - | 48M | |||||
Other Operating Expenses | - | - | - | - | -13.56M | |||||
Other Operating Expenses, Total | 57.3M | 61.09M | 71.81M | 81.31M | 70.05M | |||||
Operating Income | -162M | -162M | -138M | -52.41M | -64.12M | |||||
Interest Expense, Total | - | - | - | -3.35M | -7.27M | |||||
Interest And Investment Income | 1.1M | 1.54M | 5.96M | 6.6M | 1.65M | |||||
Net Interest Expenses | 1.1M | 1.54M | 5.96M | 3.25M | -5.62M | |||||
Currency Exchange Gains (Loss) | 3.85M | -536K | -807K | -1.73M | 521K | |||||
Other Non Operating Income (Expenses) | -7K | - | -198K | - | - | |||||
EBT, Excl. Unusual Items | -157M | -161M | -133M | -50.89M | -69.22M | |||||
Restructuring Charges | - | -2.3M | -1.7M | -5.95M | - | |||||
Gain (Loss) On Sale Of Investments | 6K | - | 198K | - | - | |||||
Asset Writedown | - | - | - | -10.4M | -2.9M | |||||
In Process R&D Expenses | - | - | - | - | -5.89M | |||||
Other Unusual Items | - | - | 22.05M | - | - | |||||
EBT, Incl. Unusual Items | -157M | -163M | -113M | -67.24M | -78.01M | |||||
Income Tax Expense | 791K | 2.5M | 1.34M | 3.58M | - | |||||
Earnings From Continuing Operations | -158M | -165M | -114M | -70.81M | -78.01M | |||||
Earnings Of Discontinued Operations | - | - | - | - | 103M | |||||
Net Income to Company | -158M | -165M | -114M | -70.81M | 25.21M | |||||
Net Income - (IS) | -158M | -165M | -114M | -70.81M | 25.21M | |||||
Net Income to Common Incl Extra Items | -158M | -165M | -114M | -70.81M | 25.21M | |||||
Net Income to Common Excl. Extra Items | -158M | -165M | -114M | -70.81M | -78.01M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -1.01 | -1.03 | -0.57 | -0.28 | 0.1 | |||||
Basic EPS - Continuing Operations | -1.01 | -1.03 | -0.57 | -0.28 | -0.3 | |||||
Basic Weighted Average Shares Outstanding | 156M | 161M | 201M | 252M | 263M | |||||
Net EPS - Diluted | -1.01 | -1.03 | -0.57 | -0.3 | 0.08 | |||||
Diluted EPS - Continuing Operations | -1.01 | -1.03 | -0.57 | -0.3 | -0.3 | |||||
Diluted Weighted Average Shares Outstanding | 156M | 161M | 201M | 252M | 272M | |||||
Normalized Basic EPS | -0.63 | -0.62 | -0.41 | -0.13 | -0.16 | |||||
Normalized Diluted EPS | -0.63 | -0.62 | -0.41 | -0.13 | -0.16 | |||||
American Depositary Receipts Ratio (ADR) | 6 | 6 | 6 | 6 | 6 | |||||
Supplemental Items | ||||||||||
EBITDA | -156M | -156M | -128M | -41.18M | -57.49M | |||||
EBITA | -161M | -161M | -138M | -52M | -63.97M | |||||
EBIT | -162M | -162M | -138M | -52.41M | -64.12M | |||||
EBITDAR | -151M | -151M | -121M | -34.32M | -57.47M | |||||
Total Revenues (As Reported) | 6.15M | 27.15M | 60.28M | 178M | - | |||||
Effective Tax Rate - (Ratio) | -0.5 | -1.53 | -1.19 | -5.32 | - | |||||
Current Domestic Taxes | - | - | 26K | - | - | |||||
Current Foreign Taxes | 791K | 2.5M | 1.31M | 3.58M | - | |||||
Total Current Taxes | 791K | 2.5M | 1.34M | 3.58M | - | |||||
Normalized Net Income | -98.32M | -100M | -83.17M | -31.8M | -43.26M | |||||
Interest on Long-Term Debt | - | - | - | - | 7.27M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 57.3M | 61.09M | 71.81M | - | - | |||||
Research And Development Expense From Footnotes | 145M | 158M | 142M | 161M | 48M | |||||
Net Rental Expense, Total | 4.68M | 4.76M | 6.74M | 6.86M | 25K | |||||
Imputed Operating Lease Interest Expense | - | - | - | 3.7M | 32.9K | |||||
Imputed Operating Lease Depreciation | - | - | - | 3.17M | -7.9K | |||||
Stock-Based Comp., COGS (Total) | 9.05M | 6.26M | 3.06M | 3.88M | - | |||||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | 11.58M | 11.98M | 8.71M | - | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | - | - | - | 8.18M | - | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | -1.16M | |||||
Total Stock-Based Compensation | 20.63M | 18.24M | 11.77M | 12.05M | -1.16M |
Select your edition
All financial news and data tailored to specific country editions
















